INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease / R. Younes, O. Govaere, S. Petta, L. Miele, D. Tiniakos, A. Burt, E. David, F.M. Vecchio, M. Maggioni, D. Cabibi, A.L. Fracanzani, C. Rosso, M.J.G. Blanco, A. Armandi, G.P. Caviglia, M.Y.W. Zaki, A. Liguori, P. Francione, G. Pennisi, A. Grieco, L. Valenti, Q.M. Anstee, E. Bugianesi. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - 115:8(2020 Aug), pp. 1289-1292. [10.14309/ajg.0000000000000676]
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease
A.L. Fracanzani;P. Francione;A. Grieco;L. Valenti;
2020
Abstract
INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Presence_of_Serum_Antinuclear_Antibodies_Does_Not.29 (1).pdf
accesso riservato
Descrizione: Articolo completo
Tipologia:
Publisher's version/PDF
Dimensione
162.87 kB
Formato
Adobe PDF
|
162.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
